Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Sunil Shah | M | 51 |
Alevin Therapeutics Ltd.
Alevin Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors. | - |
Alice Laura MacGowan | M | 48 |
Alevin Therapeutics Ltd.
Alevin Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Chris Moody | M | - |
Alevin Therapeutics Ltd.
Alevin Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors. | - |
Alison John | F | - |
Alevin Therapeutics Ltd.
Alevin Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 4 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Thomas McInally
- Persoonlijk netwerk